LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This phase I protocol will evaluate the safety and tolerability of the combination of LBH589
and paclitaxel/carboplatin. The combination of LBH589, paclitaxel/carboplatin, and
bevacizumab will also be evaluated for tolerability and preliminary antitumor activity in a
subset of patients with advanced non-small cell lung cancer.